Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR

Recruiting Phase 3 Interventional Study
Prosthetic Infection
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
436 (estimated)
Sponsor
Tourcoing Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Hip or knee Prosthetic joint infection treated by debridement, antibiotic therapy initiation and retention of prothesis (DAIR strategy) 2. Infected with at least one of the following microorganisms: 1. Staphylococcus aureus 2. Coagulase-negative staphylococci 3. Microo…
Contacts

Eric SENNEVILLE, MD PhD

0320694949

esenneville@ch-tourcoing.fr

CONTACT

Solange TREHOUX

0320694280

strehoux@ch-tourcoing.fr

CONTACT